Brief: Biophytis Presents Sarconeos (BIO101) Development Program In Sarcopenia

Biophytis SA

19/04/2022 07:46

April 19 (Reuters) - Biophytis SA  ALBPS.PA :
    * BIOPHYTIS PRESENTS SARCONEOS (BIO101) DEVELOPMENT PROGRAM
IN
SARCOPENIA AT 12TH ANNUAL INTERNATIONAL CONFERENCE ON FRAILTY
AND SARCOPENIA RESEARCH (ICFSR) IN BOSTON  APRIL 20-22, 2022
    * FOLLOWING FIRST MEETING WITH FDA IN JANUARY 2022, A SECOND
MEETING IS PLANNED IN Q3 2022 TO DISCUSS SARA DEVELOPMENT PLAN
INCLUDING PHASE 2-3 PROTOCOL. OBJECTIVE IS TO HAVE A FPI (FIRST
PATIENT IN) FOR THIS NEW STUDY AT END OF H2 2022
    * WE ALSO PLAN TO HAVE DISCUSSIONS WITH EMA DURING H2 2022,
IN
ORDER TO OBTAIN SCIENTIFIC ADVICE ON PHASE 2 RESULTS AND
PROGRESSION TOWARD A PHASE 2-3
    * THESE PLANS REMAIN SUBJECT TO REGULATORY AUTHORIZATIONS
AND
PROCEDURES, ANY DELAYS IN PATIENT RECRUITMENT OR RETENTION,
INTERRUPTIONS IN SOURCING OR SUPPLY CHAIN, AND TO
COVID-19-RELATED DELAYS

Source text for Eikon:  urn:newsml:reuters.com:*:nEQ9PNhsqa
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))